Erazo, Tatiana
Evans, Chiara M.
Zakheim, Daniel
Chu, Karen L.
Refermat, Alice Yunsi http://orcid.org/0000-0002-6517-7304
Asgari, Zahra
Yang, Xuejing
Da Silva Ferreira, Mariana
Mehta, Sanjoy
Russo, Marco Vincenzo
Knezevic, Andrea
Zhang, Xi-Ping
Chen, Zhengming
Fennell, Myles
Garippa, Ralph
Seshan, Venkatraman http://orcid.org/0000-0002-9258-2698
de Stanchina, Elisa
Barbash, Olena
Batlevi, Connie Lee http://orcid.org/0000-0002-9036-9463
Leslie, Christina S.
Melnick, Ari M. http://orcid.org/0000-0002-8074-2287
Younes, Anas http://orcid.org/0000-0002-0001-4133
Kharas, Michael G. http://orcid.org/0000-0002-1165-6991
Article History
Received: 19 December 2021
Accepted: 27 August 2022
First Online: 27 September 2022
Competing interests
: A.Y. is currently employed by AstraZeneca. Research support: Janssen, Curis, Merck, BMS, Syndax, Roche; Honorarium: Janssen, Abbvie, Merck, Curis, Epizyme, Roche, Takeda; Consulting: Biopath, Xynomics, Epizyme, Roche, Celgene, HCM. C.L.B. Research Support: Janssen, Novartis, Epizyme, Bayer, Autolus, Roche; Honorarium: Dava Oncology, TouchIME, Medscape. Consulting: Life Sci, GLG, Juno/Celgene/BMS, Seattle Genetics, Kite, Karyopharm, TG Therapeutics, ADC Therapeutics.A.M.M. Research support: Janssen Pharmaceuticals, Sanofi, and Daiichi Sankyo. Consulting: Epizyme and Constellation. Scientific advisory board of KDAC pharmaceuticals. O.B. is currently employed by GlaxoSmithKline. M.G.K. honorarium at Kumquat Biosciences and Scientific advisory board 858 Therapeutics. The remaining authors declare no competing interests.